Role of Coronary Artery and Thoracic Aortic Calcium as Risk Modifiers to Guide Antihypertensive Therapy in Stage 1 Hypertension (From the Multiethnic Study of Atherosclerosis)

The 2017 American blood pressure (BP) guidelines recommended a personalized risk-based approach to treatment in stage 1 hypertension. We sought to establish the utility of coronary artery or thoracic aortic calcium (CAC or TAC) as additional risk modifiers in this setting. We included 1859 Multiethn...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The American journal of cardiology Ročník 126; s. 45 - 55
Hlavní autoři: Elshazly, Mohamed B., Abdellatif, Amal, Dargham, Soha R., Rifai, Mahmoud Al, Quispe, Renato, Cainzos-Achirica, Miguel, Martin, Seth S., Yeboah, Joseph, Psaty, Bruce M., Post, Wendy S., Nasir, Khurram, Budoff, Matthew J., Blumenthal, Roger S., Blaha, Michael J., McEvoy, John W.
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Inc 01.07.2020
Elsevier Limited
Témata:
Age
Antihypertensives
Aorta
Arteriosclerosis
Atherosclerosis
Blood pressure
Calcification
Calcium
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Congestive heart failure
Coronary artery
Coronary artery disease
Coronary vessels
Diabetes
Drug therapy
Edema
Family medical history
Fasting
Guidelines
Heart attacks
Hospitalization
Hypertension
Pharmacology
Risk allocation
Risk groups
Stroke
Subgroups
Thorax
Triglycerides
Veins & arteries
United States > US
ISSN:0002-9149, 1879-1913, 1879-1913
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The 2017 American blood pressure (BP) guidelines recommended a personalized risk-based approach to treatment in stage 1 hypertension. We sought to establish the utility of coronary artery or thoracic aortic calcium (CAC or TAC) as additional risk modifiers in this setting. We included 1859 Multiethnic Study of Atherosclerosis participants with stage 1 hypertension. We compared adjusted HR for the composite outcome of incident atherosclerotic cardiovascular disease or heart failure across predefined categories of either CAC or TAC (0, 1 to 100, or >100) in: (1) the full sample; (2) 4 high-risk subgroups recommended for pharmacotherapy to a BP goal <130/80 mm Hg, and (3) low-risk subgroup not eligible for pharmacotherapy. We also estimated the 10-year number-needed-to-treat (NNT10) to a systolic BP <130 mm Hg as extrapolated from meta-analyses. Mean age was 62.8 ± 9.4 years, 46% were female and there were 300 events over a median follow-up of 13.8 years. The absolute event rate was 4.1 to 10.8 per 1,000 person-years among high-risk participants with CAC = 0, but 28.4 among low-risk participants with CAC >100. CAC >100 was independently associated with a higher relative risk of events compared with CAC = 0 (e.g., adjusted HR [9.5 (1.8 to 18.7)] in the low-risk subgroup). NNT10 for CAC = 0 were 3 to 5 times higher than those for CAC >100 in all analyses. TAC was not a reliable risk modifier in our study. In conclusion, CAC, but not TAC, can further guide risk-based allocation of treatment in stage 1 hypertension and should be considered as a risk modifier in future guidelines.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0002-9149
1879-1913
1879-1913
DOI:10.1016/j.amjcard.2020.02.036